Robert J. Hombach - Net Worth and Insider Trading
Robert J. Hombach Net Worth
The estimated net worth of Robert J. Hombach is at least $537,291 dollars as of 2023-06-04. Robert J. Hombach is the Corporate Vice President & CFO of Baxter International Inc and owns about 12,612 shares of Baxter International Inc (BAX) stock worth over $521,254. Robert J. Hombach is also the Director of Aptinyx Inc and owns about 229,100 shares of Aptinyx Inc (APTX) stock worth over $16,037. Details can be seen in Robert J. Hombach's Latest Holdings Summary section.
Transaction Summary of Robert J. Hombach
Robert J. Hombach Insider Ownership Reports
Based on ownership reports from SEC filings, as the reporting owner, Robert J. Hombach owns 6 companies in total, including Aptinyx Inc (APTX) , CarMax Inc (KMX) , and Biomarin Pharmaceutical Inc (BMRN) among others .
Click here to see the complete history of Robert J. Hombach’s form 4 insider trades.
Insider Ownership Summary of Robert J. Hombach
|Ticker||Comapny||Transaction Date||Type of Owner|
|BMRN||Biomarin Pharmaceutical Inc||2017-09-29||director|
|BXLT||Baxalta Inc||2016-06-03||EVP. CFO and COO|
|BAX||Baxter International Inc||2010-07-05||Corporate Vice President & CFO|
Robert J. Hombach Latest Holdings Summary
Robert J. Hombach currently owns a total of 2 stocks. Among these stocks, Robert J. Hombach owns 12,612 shares of Baxter International Inc (BAX) as of July 22, 2013, with a value of $521,254 and a weighting of 97.02%. Robert J. Hombach also owns 229,100 shares of Aptinyx Inc (APTX) as of November 12, 2021, with a value of $16,037 and a weighting of 2.98%.
Latest Holdings of Robert J. Hombach
|Ticker||Comapny||Latest Transaction Date||Shares Owned||Current Price ($)||Current Value ($)|
|BAX||Baxter International Inc||2013-07-22||12,612||41.33||521,254|
Holding Weightings of Robert J. Hombach
Robert J. Hombach Form 4 Trading Tracker
According to the SEC Form 4 filings, Robert J. Hombach has made a total of 0 transactions in Baxter International Inc (BAX) over the past 5 years. The most-recent trade in Baxter International Inc is the sale of 47,452 shares on July 22, 2013, which brought Robert J. Hombach around $4 Million.
According to the SEC Form 4 filings, Robert J. Hombach has made a total of 6 transactions in Aptinyx Inc (APTX) over the past 5 years, including 6 buys and 0 sells. The most-recent trade in Aptinyx Inc is the acquisition of 80,000 shares on November 12, 2021, which cost Robert J. Hombach around $192,000.
Insider Trading History of Robert J. Hombach
Robert J. Hombach Trading Performance
GuruFocus tracks the stock performance after each of Robert J. Hombach's buying transactions within different timeframes. To be detailed, the average return of stocks after 3 months bought by Robert J. Hombach is 12.43%. GuruFocus also compares Robert J. Hombach's trading performance to market benchmark return within the same time period. The performance of stocks bought by Robert J. Hombach within 3 months outperforms 4 times out of 6 transactions in total compared to the return of S&P 500 within the same period.
You can select different timeframes to see how Robert J. Hombach's insider trading performs compared to the benchmark.
Performance of Robert J. Hombach
Average Relative Return
|1 Month||3 Months||6 Months||1 Year||2 Years||3 Years|
|Relative Return to S&P 500(%)||9.32||12.67||-14.6||-49.01||-40.23||-53.79|
Robert J. Hombach Ownership Network
Ownership Network List of Robert J. Hombach
Ownership Network Relation of Robert J. Hombach
Robert J. Hombach Owned Company Details
What does Aptinyx Inc do?
Aptinyx Inc is a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of novel, proprietary, synthetic small molecules for the treatment of brain and nervous system disorders. Its pipeline products are NYX-2925, NYX-458, and NYX-783. NYX-2925 is a novel, oral, small-molecule NMDA receptor modulator in clinical development as a therapy for chronic pain. NYX-2925 works by enhancing synaptic plasticity, a mechanism uniquely suited to addressing chronic pain, and NYX-783 is an NMDA receptor modulating small molecule in clinical development as a therapy for post-traumatic stress disorder.
Who are the key executives at Aptinyx Inc?
Robert J. Hombach is the director of Aptinyx Inc. Other key executives at Aptinyx Inc include 10 percent owner Bain Capital Life Sciences Partners, Lp , 10 percent owner Jeffrey Lawrence Schwartz , and 10 percent owner Bcip Life Sciences Associates, Lp .
Aptinyx Inc (APTX) Insider Trades Summary
Over the past 18 months, Robert J. Hombach made no insider transaction in Aptinyx Inc (APTX). Other recent insider transactions involving Aptinyx Inc (APTX) include a net purchase of 100,000 shares made by Norbert G Riedel , and a net purchase of 17,700 shares made by Joan W. Miller .
In summary, during the past 3 months, insiders sold 0 shares of Aptinyx Inc (APTX) in total and bought 0 shares, with a net sale of 0 shares. During the past 18 months, 0 shares of Aptinyx Inc (APTX) were sold and 117,700 shares were bought by its insiders, resulting in a net purchase of 117,700 shares.
Aptinyx Inc (APTX)'s detailed insider trading history can be found in Insider Trading Tracker table.
Aptinyx Inc Insider Transactions
Robert J. Hombach Mailing Address
Above is the net worth, insider trading, and ownership report for Robert J. Hombach. You might contact Robert J. Hombach via mailing address: C/o Baxalta Incorporated, 1200 Lakeside Drive, Bannockburn Il 60015.